Why the study?
Does the dopamine (DA1) receptor agonist fenoldopam induce vasodilation in human vasculature in vivo and in vitro?
Does the dopamine (DA1) receptor agonist fenoldopam induce vasodilation in human vasculature in vivo and in vitro?
This study demonstrates the presence of vasodilatory vascular dopamine (DA1) receptors in human vasculature that mediate relaxation when stimulated by fenoldopam.
Answers are grounded in this paper and cite their sources.
Fenoldopam vasodilation via DA1 receptors merits clinical investigation; leaves open therapeutic translation from Level 5 data.
This study was designed to investigate dopaminergic mechanisms in human vasculature using the selective vascular dopamine receptor agonist fenoldopam in vivo and in vitro. In vivo, forearm blood flow was measured plethysmographically and in vitro isolated rings of human blood vessels from a variety of sites were used for tissue bath studies. Intra-arterial fenoldopam markedly increased forearm blood flow, this effect was antagonised by (R) sulpiride, a vascular dopamine (DA1) antagonist, but not by metoclopramide, a neuronal (DA2) antagonist, or by guanethidine, an adrenergic neurone blocking agent. In vitro, fenoldopam relaxed preconstricted human renal, mesenteric and lumbar arteries, but not saphenous vein in a concentration dependent manner. (RS) sulpiride and SCH 23390 competitively antagonised this effect. These studies demonstrate the presence of a vasodilatory vascular dopamine receptor in man both in vivo and in vitro.
No takes yet. Share an insight, caveat, or question.
Hughes et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: